Stockscreener 앱 받기
5.85
4.72%
-0.29
Nuvation Bio Inc 주식(NUVB)의 최신 뉴스
Aug Closing: Whats the analyst consensus on Surrozen IncLong Setup & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Is Nuvation Bio (NUVB) Pricing In Its Sharp Swings Or A Long Runway For Growth - Yahoo Finance
Signal Recap: Should I invest in KORE Group Holdings Inc before earningsJuly 2025 Earnings & Fast Moving Stock Trade Plans - baoquankhu1.vn
A Look At Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Licensing Deal - Yahoo Finance
Is Nuvation Bio Inc stock undervalued right nowMarket Growth Report & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Eisai and Nuvation Bio ink licensing deal for taletrectinib - The Pharma Letter
14 Best Booming Stocks to Buy Right Now - Insider Monkey
Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib - Insider Monkey
Jones Trading raises Nuvation Bio stock price target to $12 on safusidenib study - Investing.com Australia
Q1 EPS Estimates for Nuvation Bio Boosted by HC Wainwright - MarketBeat
Nuvation Bio (NUVB) Expands Global Taletrectinib Rights With Eisai Collaboration And Licensing Deal - simplywall.st
Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens - TechStock²
Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights
Nuvation Bio stock price target lowered to $17 at H.C. Wainwright - Investing.com Nigeria
Weekly Earnings: Will Nuvation Bio Inc stock outperform value stocksJobs Report & Free Safe Capital Growth Stock Tips - moha.gov.vn
Down 24% in 4 Weeks, Here's Why Nuvation Bio (NUVB) Looks Ripe for a Turnaround - Yahoo Finance
Nuvation Bio stock rating reiterated at Market Outperform by Citizens - Investing.com Nigeria
Nuvation Bio and Eisai license Taletrectinib rights outside US, China and Japan for $230 M - BioSpectrum Asia
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan - Quamnet
Nuvation Bio Faces Challenges Amidst Financial and Market Turbulence - StocksToTrade
NUVB Stock Dips Amidst Market Uncertainty and Strategic Pressure - StocksToTrade
Expert Outlook: Nuvation Bio Through The Eyes Of 9 Analysts - Benzinga
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
NUVB Stock Surges Following Promising Expansion News - timothysykes.com
Nuvation Bio (NYSE:NUVB) Shares Gap Down After Analyst Downgrade - MarketBeat
HC Wainwright Has Lowered Expectations for Nuvation Bio (NYSE:NUVB) Stock Price - MarketBeat
Nuvation Stocks Dip on Hookup with Japanese Firm - Baystreet.ca
Nuvation Bio (NUVB): HC Wainwright & Co. Lowers Price Target, Ma - GuruFocus
Nuvation Bio Expands Global Reach with Eisai Partnership - TipRanks
Nuvation Bio Reports Preliminary Fourth Quarter And Full Year 2025 Financial Results And Provides 2026 Outlook Ahead Of 44Th Annual J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Nuvation Bio Signs License and Collaboration Agreement With Eisai - TradingView — Track All Markets
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan - The AI Journal
Nuvation Bio and Eisai enter into exclusive licensing agreement for taletrectinib in Europe and additional countries outside U.S., China and Japan - marketscreener.com
Wall Street Analysts Believe Nuvation Bio (NUVB) Could Rally 25.14%: Here's is How to Trade - MSN
Why Nuvation Bio Inc. Warrants stock gets analyst attentionWeekly Stock Recap & Fast Gain Swing Trade Alerts - Улправда
Hennion & Walsh Asset Management Inc. Has $1.26 Million Stock Holdings in Nuvation Bio Inc. $NUVB - MarketBeat
Moving Averages: How Nuvation Bio Inc stock reacts to bond yieldsVolume Spike & Long-Term Investment Growth Plans - moha.gov.vn
Nuvation Bio stock falls as UBS starts coverage; NUVB investors eye JPM conference next week - TechStock²
A Look At Nuvation Bio (NUVB) Valuation After The Recent UBS Downgrade - Sahm
Nuvation Bio Inc. (NUVB) Stock Analysis: 32.81% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Is Nuvation Bio Inc. stock positioned for long term growth2025 Major Catalysts & Technical Pattern Recognition Alerts - ulpravda.ru
How Nuvation Bio Inc. stock reacts to oil pricesPortfolio Gains Report & Consistent Profit Alerts - ulpravda.ru
How Nuvation Bio Inc. stock reacts to bond yieldsJuly 2025 Momentum & Low Drawdown Investment Ideas - ulpravda.ru
Is Nuvation Bio Inc. stock safe for conservative investorsMarket Risk Report & Daily Momentum Trading Reports - ulpravda.ru
Why Nuvation Bio Inc. Class stock remains stableJuly 2025 Earnings & Safe Investment Capital Preservation Plans - ulpravda.ru
Why Nuvation Bio Inc. stock is trending among retail tradersWeekly Trade Summary & Weekly Chart Analysis and Guides - ulpravda.ru
Aug Swings: Why Nuvation Bio Inc. stock is trending among retail traders2025 Price Targets & Long-Term Growth Portfolio Plans - ulpravda.ru
How Nuvation Bio Inc. stock reacts to global recession fears2025 Short Interest & Step-by-Step Swing Trade Plans - ulpravda.ru
RBC Raises Price Target on Nuvation Bio to $9 From $8, Keeps Outperform, Speculative Risk - MarketScreener
UBS Initiates Coverage of Nuvation Bio (NUVB) with Neutral Recommendation - Nasdaq
Nuvation Bio Inc.'s (NYSE:NUVB) institutional investors lost 5.2% last week but have benefitted from longer-term gains - Yahoo Finance
UBS initiates Nuvation Bio stock with Neutral rating, $10 price target - Investing.com
4.73%
0.92%
자본화:
|
볼륨(24시간):